Telix Pharmaceuticals Limited
TLPPF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $783 | $503 | $160 | $8 |
| % Growth | 55.8% | 213.9% | 2,007.6% | – |
| Cost of Goods Sold | $274 | $188 | $131 | $37 |
| Gross Profit | $510 | $314 | $29 | -$30 |
| % Margin | 65.1% | 62.6% | 18.3% | -391.9% |
| R&D Expenses | $121 | $129 | $58 | $34 |
| G&A Expenses | $122 | $79 | $49 | $35 |
| SG&A Expenses | $207 | $134 | $87 | $47 |
| Sales & Mktg Exp. | $85 | $55 | $38 | $6 |
| Other Operating Expenses | $99 | $0 | -$42 | $0 |
| Operating Expenses | $428 | $263 | $103 | $81 |
| Operating Income | $82 | $52 | -$92 | -$81 |
| % Margin | 10.5% | 10.3% | -57.4% | -1,069.6% |
| Other Income/Exp. Net | -$26 | $0 | -$7 | -$18 |
| Pre-Tax Income | $56 | $3 | -$99 | -$99 |
| Tax Expense | $6 | -$2 | $5 | -$19 |
| Net Income | $50 | $5 | -$104 | -$81 |
| % Margin | 6.4% | 1% | -65% | -1,059.9% |
| EPS | 0.15 | 0.016 | -0.34 | -0.29 |
| % Growth | 820.2% | 104.8% | -17.2% | – |
| EPS Diluted | 0.14 | 0.016 | -0.34 | -0.29 |
| Weighted Avg Shares Out | 331 | 319 | 311 | 282 |
| Weighted Avg Shares Out Dil | 345 | 324 | 311 | 282 |
| Supplemental Information | – | – | – | – |
| Interest Income | $11 | $1 | $0 | $0 |
| Interest Expense | $21 | $14 | $0 | $0 |
| Depreciation & Amortization | $6 | $7 | $5 | $5 |
| EBITDA | $98 | $23 | -$93 | -$70 |
| % Margin | 12.5% | 4.6% | -58% | -922.5% |